Becton, Dickinson and Company (BDX)

Market Cap	59.07B
Revenue (ttm)	20.64B
Net Income (ttm)	1.73B
Shares Out	287.14M
EPS (ttm)	5.94
PE Ratio	34.62
Forward PE	14.21
Dividend	$4.16 (2.02%)
Ex-Dividend Date	Mar 10, 2025

Volume	1,322,788
Open	204.45
Previous Close	201.78
Day's Range	202.41 - 206.34
52-Week Range	193.03 - 251.99
Beta	0.38
Analysts	Strong Buy
Price Target	275.71 (+34.03%)
Earnings Date	May 1, 2025

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 73,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX
• Website: https://www.bd.com

Financial Performance

In 2024, BDX's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.

Analyst Forecast

According to 7 analysts, the average rating for BDX stock is "Strong Buy." The 12-month stock price forecast is $275.71, which is an increase of 34.03% from the latest price.

Price Target

$275.71

(34.03% upside)

Analyst Consensus: Strong Buy